InspireMD (NYSE:NSPR) Now Covered by StockNews.com

Research analysts at StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.

A number of other equities research analysts have also recently weighed in on NSPR. Piper Sandler reiterated an “overweight” rating and set a $4.50 price target on shares of InspireMD in a research report on Tuesday, September 17th. Lake Street Capital assumed coverage on InspireMD in a research report on Wednesday. They set a “buy” rating and a $5.00 price objective for the company.

InspireMD Stock Up 1.0 %

Shares of NYSE NSPR opened at $3.17 on Thursday. The stock has a market capitalization of $82.69 million, a price-to-earnings ratio of -4.23 and a beta of 0.98. InspireMD has a 52 week low of $1.81 and a 52 week high of $3.42. The firm has a 50-day simple moving average of $2.65 and a 200-day simple moving average of $2.67.

InspireMD (NYSE:NSPR) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The business had revenue of $1.81 million for the quarter, compared to analyst estimates of $1.74 million. During the same quarter in the previous year, the firm earned ($0.15) EPS. As a group, equities research analysts expect that InspireMD will post -0.79 EPS for the current year.

Institutional Trading of InspireMD

An institutional investor recently bought a new position in InspireMD stock. Parkman Healthcare Partners LLC acquired a new position in shares of InspireMD, Inc. (NYSE:NSPR) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 104,081 shares of the company’s stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned 0.42% of InspireMD at the end of the most recent quarter. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.